On September 16, Luye Pharmaceutical Group announced that its subsidiary, Luye Pharmaceuticals (Switzerland), has reached an agreement with Esteve Pharmaceuticals, S.A. (ESTEVE), granting the latter the exclusive right to commercialize the Mindo Day transdermal patch of Liss in Spain. Liss’ Mindoday transdermal patch is used to treat mild and moderate dementia related to Alzheimer’s disease. It was independently developed by Luye Pharmaceuticals and has recently been approved for marketing in Spain1. Liss’ Mindo Day transdermal patch is an important strategic complement to ESTEVE’s product portfolio in the field of central nervous system therapy, and the company has extensive experience in this field. Lis' Mindo Day Transdermal Patch
Xavier Valera, Managing Director of ESTEVE Spain, said: Through this cooperation, we can introduce this innovative treatment plan to Spain and serve as a useful supplement to our product portfolio in the field of neurological diseases and improve the quality of life of patients. Bruno Delie, General Manager of Luye Pharma (Switzerland), said: The cooperation with ESTEVE is an important milestone for us to serve the European market and to solve the unmet needs of local elderly patients. With ESTEVE's rich experience in the field of central nervous diseases and a strong business operation system, I believe that this new treatment option can be brought to local patients as soon as possible. We are committed to making unremitting efforts to improve the quality of life of people with dementia, their families, friends and caregivers. About Liss' Mindo Day Transdermal Patch Liszmin's transdermal patch is a twice-weekly innovative form of Liszmin's patch for the treatment of mild to moderate dementia related to Alzheimer's disease1. The product is developed by Luye Pharma's proprietary transdermal drug delivery technology platform, and is one of the company's core products in the field of central nervous system therapy. 1. Listigmine is a cholinesterase inhibitor drug. Such drugs can improve cognitive functions such as memory and thinking by increasing the amount of certain natural substances in the brain and amplifying the communication channels between nerve cells, which are used in patients with mild to moderate Alzheimer’s disease The activity is weak. At present, the drug is mainly administered in the form of tablets and patches for daily administration. 2. Lisz's Mingtori transdermal patch will be registered in major markets around the world, including Europe, Japan and China. In September 2020, the product was approved by the Drug Evaluation Center of the National Medical Products Administration of China to enter the clinical trial phase in China. In February 2021, Towa Pharmaceutical Co., Ltd. was granted the exclusive right to develop and commercialize Liss’s Mingta day transdermal patch in Japan. The product is about to start phase III clinical trials in Japan. Luye Pharma also plans to register the product in other countries and regions.
September 18, 2021
